 NEWTOWN, Pa., Aug. 11, 2021 GLOBE NEWSWIRE -- Helius Medical Technologies, Inc. Nasdaq: HSDT TSX: HSM Helius or the Company, a neurotech company focused on neurological wellness, today announced that, effective August 10, 2021, its independent directors approved an equity award under Helius 2021 Inducement Plan, as a material inducement to an individual entering into employment with the Company. The equity award was approved in accordance with Nasdaq Listing Rule 5635c4, which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan. 